Hans-Christoph Diener (Medical Faculty of the University of Duisburg-Essen, Institute for Medical Informatics, Biometry and Epidemiology, Essen, Germany), talks to us around the highlights of his recently published co-authored review article entitled: Patent Foramen Ovale Closure—Addressing the Unmet Need for Reducing the Risk of Ischemic Stroke, freely available to access here.
Questions
1. What is the current understanding of the role a patent foramen ovale (PFO) plays in the risk and recurrence of cryptogenic strokes? (0:05)
2. What treatment strategies exist for patients at risk of a recurrent stroke, and how does the presence of a PFO influence treatment selection? (0:45)
3. Can you explain why optimal management of stroke requires multidisciplinary commitment? (1:33)
4. What are the key aspects of minimizing stroke risk, especially in patients with PFO, for neurologists and cardiologists? (2:29)
Speaker disclosures: Hans-Christoph Diener has received honoraria for participation in clinical trials, contribution to advisory boards or oral presentations from: Abbott, Bayer Vital, Bristol Myers Squibb, Boehringer Ingelheim, Daiichi-Sankyo, Medtronic, Pfizer, Portola, Sanofi-Aventis, and WebMD Global. Financial support for research projects has been provided by Boehringer Ingelheim. Hans-Christoph Diener chairs the Treatment Guidelines Committee of the German Society of Neurology and contributed to the European Heart Rhythm Association and European Society of Cardiology guidelines for the treatment of atrial fibrillation.
Support: Interview and filming supported by Abbott.
Filmed during a remote video call with Hans-Christoph Diener, June 2020.
